Frederic de Sauvage, Vice President, Molecular Biology, and Jennifer Low, Global Clinical Lead GDC-0449, discuss Phase I data on Hedgehog Pathway Inhibitor in medulloblastoma and basal cell carcinoma.

Read the transcript of the interview.